Benefits of high versus low dose upadacitinib as maintenance treatment in ulcerative colitis patients who were responders to 8-week induction with upadacitinib: Results from the U-ACHIEVE phase 3 maintenance trial

被引：0

作者：

Feagan, Brian ^{[1
]}

Parkes, Gareth ^{[2
,3
]}

Juillerat, Pascal ^{[4
,5
]}

Gecse, Krisztina ^{[6
]}

Yao, Xuan ^{[7
]}

Zhou, Wen ^{[7
]}

Deng, Huiwen ^{[7
,8
]}

Ilo, Dapo ^{[7
]}

Gonzalez, Yuri Sanchez ^{[7
]}

Higgins, Peter D. R. ^{[9
]}

机构：

[1] Western Univ, Div Gastroenterol, London, ON, Canada

[2] Barts Hlth NHS Trust, London, England

[3] Barts & London Queen Marys Sch Med & Dent, London, England

[4] Inselspital Bern, Dept Visceral Surg & Med, Gastroenterol, Bern, Switzerland

[5] Bern Univ, Bern, Switzerland

[6] Amsterdam UMC, Locat AMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

[7] AbbVie Inc, Chicago, IL USA

[8] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA

[9] Univ Michigan, Div Gastroenterol, Ann Arbor, MI 48109 USA

来源：

SWISS MEDICAL WEEKLY | 2023年 / 153卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IBD-1

引用

页码：2S / 2S

页数：1

共 33 条

[1] Benefits of High versus Low Dose Upadacitinib as Maintenance Treatment in Ulcerative Colitis Patients Who Were Responders to 8-week Induction with Upadacitinib: Results From the U-ACHIEVE Phase 3 Maintenance Trial
Feagan, Brian G.
Parkes, Gareth
Juillerat, Pascal
Gecse, Krisztina
Yao, Xuan
Zhou, Wen
Deng, Huiwen
Ilo, Dapo
Sanchez-Gonzalez, Yuri
Higgins, Peter D.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S496 - S496
[2] Benefits of high versus low dose upadacitinib as maintenance treatment in ulcerative colitis
Feagan, Brian
Parkes, Gareth
Juillerat, Pascal
Gecse, Krisztina
Yao, Xuan
Zhou, Wen
Deng, Huiwen
Ilo, Dapo
Gonzalez, Yuri Sanchez
Higgins, Peter
GUT, 2023, 72 (SUPPL_2) : A72 - A73
[3] Impact of Inflammatory Burden on Efficacy of Upadacitinib Maintenance Therapy in Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study
Feagan, Brian G.
Colombel, Jean-Frederic
Torres, Joana
Fujii, Toshimitsu
Zhou, Wen
Yao, Xuan
Sanchez-Gonzalez, Yuri
Ilo, Dapo
Roblin, Xavier
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S515 - S516
[4] Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Final Results From the Phase 3 U-ACHIEVE Maintenance Study
Vermeire, Severine
Danese, Silvio
Zhou, Wen
Yao, Xuan
Ilo, Dapo
Liu, John
Hebuterne, Xavier
Lindsay, James
Sanchez-Gonzalez, Yuri
Higgins, Peter D.
Colombel, Jean-Frederic
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S521 - S522
[5] The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications
Colombel, J. F.
Panaccione, R.
Nakase, H.
Burmester, G.
Cohen, S. B.
Mease, P.
Guttman-Yassky, E.
Liu, J.
Zhou, W.
Ilo, D.
Higgins, P.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I514 - I514
[6] The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications
Colombel, J. F.
Panaccione, R.
Nakase, H.
Burmester, G.
Cohen, S. B.
Mease, P.
Guttman-Yassky, E.
Liu, J.
Zhou, W.
Ilo, D.
Higgins, P.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I514 - I514
[7] THE SAFETY PROFILE OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS IN THE PHASE 3 U-ACHIEVE STUDY IS CONSISTENT WITH THAT IN APPROVED INDICATIONS
Colombel, Jean Frederic
Panaccione, Remo
Nakase, Hiroshi
Burmester, Gerd R.
Cohen, Stanley B.
Mease, Philip
Guttman-Yassky, Emma
Liu, Jianzhong
Zhou, Wen
Ilo, Dapo
Higgins, Peter D.
GASTROENTEROLOGY, 2022, 162 (07) : S967 - S967
[8] The effects of maintenance therapy with upadacitinib on abdominal pain, bowel urgency, and fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 U-ACHIEVE maintenance results
Danese, S.
Tran, J.
D'Haens, G.
Rubin, D. T.
Aoyama, N.
Zhou, W.
James, B.
Yao, X.
Gonzalez, Y. Sanchez
Panaccione, R.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I008 - I009
[9] Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
Vermeire, Severine
Danese, Silvio
Zhou, Wen
Ilo, Dapo
Klaff, Justin
Levy, Gweneth
Yao, Xuan
Chen, Su
Gonzalez, Yuri Sanchez
Hebuterne, Xavier
Lindsay, James
Higgins, Peter D. R.
Cao, Qian
Nakase, Hiroshi
Colombel, Jean-Frederic
Loftus, Edward V., Jr.
Panaccione, Remo
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 976 - 989
[10] Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study
Danese, Silvio
Vermeire, Severine
Zhou, Wen
Pangan, Aileen
Siffledeen, Jesse
Hebuterne, Xavier
Nakase, Hiroshi
Chen, Minhu
Higgins, Peter
Sanchez-Gonzalez, Yuri
Huang, Bidan
Xian, Wangang
Liu, Jianzhong
Weinreich, Michael
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S312 - S313

← 1 2 3 4 →